Dilated cardiomyopathy (DCM) is characterized by ventricular dilation associated with systolic dysfunction, which could be caused by mutations in lamina/C gene (LMNA). LMNA-linked DCM is severe in males in both human patients and a knock-in mouse model carrying a homozygous p.H222P mutation (Lmna H222P/H222P ). The aim of this study was to investigate the molecular mechanisms underlying the gender difference of LMNA-linked DCM.
Introduction
Dilated cardiomyopathy (DCM), a primary cardiac muscle disorder characterized by ventricular chamber dilation and systolic dysfunction, 1 is the major cause of chronic heart failure (CHF) and the most common indication for cardiac transplantation. 2 Underlying aetiologies include genetic, viral, toxic agents like alcohol, mitochondrial, and metabolic disorders. 2 It is known that familial occurrence is seen in 30-40% of DCM patients. 3 To date, mutations in more than 30 genes encoding components of sarcomere, sarcolemma, cytoskeletons, or nuclear envelope have been discovered in patients with DCM, 4 and 8% of familial and sporadic DCM may be caused by mutations in LMNA encoding lamin A/C. 5 DCM occurs more frequently in men than in women (male to female ratio: 2.5), 6 and a recent study revealed significant gender differences in cardiac phenotypes such as a higher mortality and severer cardiac dysfunction in male DCM patients carrying LMNA mutation. 7 It has been suggested that gonadal hormones, such as testosterone and oestrogens, may explain the gender difference in cardiac phenotypes. Results from in vitro and in vivo studies suggest that oestrogen may play a pivotal role, 8, 9 in part due to protective actions of female hormones, which was evidenced by increased cardiovascular risk in women after menopause and by cardiovascular benefits of oestrogen replacement therapy. 9 However, mechanisms for the gender difference in DCM remain unknown.
We have established a 'knock-in' mouse carrying a p.H222P mutation of Lmna.
10 Homozygous knock-in mice (Lmna H222P/H222P
) developed DCM phenotypes, including progressive left ventricular (LV) dilation and contractile dysfunction from 2 and 4 months of age in males and females, respectively. 10 Lmna H222P/H222P male mice displayed more prominent abnormalities in cardiac function than females, and they died of CHF between 4 and 10 months of age, while female mice died at 6 and 13 months of age, 10 indicating that the Lmna H222P/H222P mice are a good model for studying the gender difference in the LMNA-linked DCM. On the other hand, no gender difference was observed in another knock-in mouse model with a LMNA mutation, p.delK32, 11 suggesting
that not all of LMNA mutations were associated with the gender difference.
In this study, we first identified a LMNA mutation, p.R225X, in a DCM family in which apparent gender difference in clinical course of DCM was observed. Transfection experiments of neonatal rat cardiomyocytes (NRCs) with the normal or mutant LMNA construct revealed that the p.R225X and p.H222P mutations induced nuclear accumulation of endogenous androgen receptors (AR), while such phenomena were not found with normal or p.delK32 mutation. The nuclear accumulation of AR was accompanied by testosterone-induced nuclear translocation of four-and-a-half LIM protein-2 (FHL2) and serum response factor (SRF), which were involved in the cardiac remodelling process. In vivo studies revealed the adverse effect of testosterone in the cardiac function and pathological changes in the heart of Lmna H222P/H222P mice.
We report here the involvement of AR and testosterone as a molecular basis for the gender difference in the progression of DCM caused by specific LMNA mutations.
Methods
Experimental details including methods of anaesthesia are described in Supplementary Information.
Mutational analysis
All human subjects and tissues were collected in accordance with the principles outlined in the Declaration of Helsinki. Whole-exome and sequencing analyses were performed with genomic DNA samples obtained from the subjects after given informed consent. The protocol for research was approved by the Ethics Reviewing Committees of Medical Research Institute, Tokyo Medical and Dental University, and Nara Medical University.
Heart tissues
Paraffin-embedded LV myocardial tissues obtained at autopsy from three male patients with DCM carrying the p.R225X mutation, from two male patients with DCM carrying no LMNA mutation, and from two control subjects without DCM were analysed. Informed consent was given from relatives of each subject. Heart samples from the Lmna H222P/H222P 10 (n ¼ 4), guanylyl cyclase A knock out (GC-A KO) 12 (n ¼ 3), and transverse aortic constriction (TAC) 13 (n ¼ 2) mice were prepared, as described previously. 10 
Immunofluorescence microscopy
All tissue sections and cells were prepared for immunofluorescence microscopy and analysed as described previously.
14,15
Animals
Establishment of Lmna H222P/H222P mouse line was reported previously. 10 Mice were fed with a chow diet and housed in a barrier facility. All care and experimental procedures of animals were in accordance with the guidelines for the Care and Use of Laboratory Animals published by the National Institute of Health (NIH Publication, eighth edition, 2011) and subjected to prior approval by the local animal protection authority in Tokyo Medical and Dental University.
Castration and ovariectomy
Six-week-old male and female wild-type (WT, Lmna +/+ ) and Lmna H222P/ H222P mice before puberty underwent bilateral castration and ovariectomy, respectively, under anaesthesia. mice, respectively). Testosterone-or flutamide-containing tubes were incubated in the saline at 378 for 24 h before implantation to avoid a surge-like release after implantation. The implanted tubes were not removed throughout the experiments.
Treatment with testosterone or flutamide

Echocardiography, electrocardiography (ECG), and blood pressure measurement
Transthoracic echocardiography, electrocardiography (ECG) analysis, and measurement of systolic blood pressure and heart rate were performed, as described previously.
17,18
Histopathological examinations
Histopathological examination using haematoxylin -eosin or Masson's trichrome staining was done by the standard methods (n ¼ 4, each group). Measurement of interstitial fibrosis area and quantitative analysis of collagen in the heart were performed (n ¼ 6, each group), as described previously. 18 
Ribonucleic acid (RNA) isolation and quantitative expression analysis
Total RNA extraction, complementary deoxyribonucleic acid (cDNA) synthesis, and real-time reverse transcription (RT) -polymerase chain reaction (PCR) analysis were performed (n ¼ 6 in each group) as described previously. 18 Relative steady-state levels of messenger RNA (mRNA)
were calculated using a comparative Ct (DdCT) method. 19 Individual expression values were normalized against the level of Gapdh mRNA.
Protein extraction and immunoblotting
Total cellular protein was extracted (n ¼ 4, each group) as described previously. 15 Nuclear protein fraction was prepared (n ¼ 8, each group) using NE-PER Nuclear and Cytoplasmic Extraction Regents (Pierce). Western blotting analysis was performed using primary antibodies against b-myosin heavy chain (bMHC), atrial natriuretic peptide (ANP), AR, SRF, FHL2, emerin, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz). The signal obtained for GAPDH was used as an internal control to normalize the amounts of protein on the immunoblots.
Measurement of serum testosterone level
Blood samples were obtained by heart puncture at time of necropsy and serum testosterone level was measured by radioimmunoassay using a DPC total testosterone kit (Mitsubishi chemical Medicine).
Statistical analysis
Phenotypic data were acquired by observers who were blinded to the genotype of mice. Numerical data were expressed as means + SEM. Statistical differences were analysed using two-way analysis of variance (ANOVA) and then evaluated using a Tukey adjustment for the post hoc test. Survival curves were drawn for each group with the Kaplan-Meier method and the differences were compared by a log-rank test. A P-value ,0.05 was considered to be statistically significant.
Results
Mutational analysis
We found a DCM family in which affected males had severer symptoms and phenotypes than females at the time of onset ( Figure 1 and see Supplementary material online, Table S1 ); all affected males had abnormalities both in cardiac conduction system and cardiac function at around the age of 30s to early 40s, whereas affected females had abnormalities in the cardiac conduction system at around the age of 40s and developed mild cardiac dysfunction later identified several sequence variations (see Supplementary material online, Figure 2A ). In contrast, no apparent differences in the localization of ERa and ERb were observed among the transfected NRCs (see Supplementary material online, Figure S1 ). On the other hand, nuclear accumulation of AR was not evident in HeLa cells transfected with the Flag-tagged WT or mutant LMNA constructs (see Supplementary material online, Figure S2 ). These observations implied that the cardiomyocyte-specific nuclear accumulation of AR was associated with specific LMNA mutations exhibiting the gender difference.
Nuclear accumulation of AR in the heart muscle
Because the findings in the transfection experiments might be due to the overexpression of LMNA with mutations, we next investigated whether the nuclear accumulation of AR could be found in the heart muscle carrying the LMNA mutations. AR was found mainly in the cytoplasm in heart samples from a control and a DCM patient without any LMNA mutations, Androgen receptor in gender difference of LMNA-linked DCM whereas the nuclear localization of AR was obviously increased in the heart samples from patients with p.R225X mutation ( Figure 3B ) and Lmna H222P/H222P mice ( Figure 3C and see Supplementary material online, Figure S3a ). We also investigated whether or not the nuclear accumulation of AR was observed in the hearts from GC-A KO mice 12 and TAC-operated mice, 13 because they were mouse models for cardiac hypertrophy, of which male mice showed more prominent cardiac phenotypes. However, no apparent change in the localization of AR was observed in both mouse models (see Supplementary material online, Figure S4 ), indicating that the nuclear AR accumulation in the cardiomyocytes was associated with specific LMNA mutations. In addition, accumulation of AR co-factors, SRF and FHL2, which are known to be involved in the cardiac remodelling, 20, 21 was observed in the nuclei of hearts from the male patients with p.R225X (see Supplementary material online, Figure  S5 ). Furthermore, the nuclear accumulation of SRF and FHL2 was observed in the hearts from male Lmna H222P/H222P
, but not from female mice (see Supplementary material online, Figures S3 and S6) . It was therefore confirmed in vivo that the nuclear accumulation of AR was accompanied by the nuclear translocation of SRF and FHL2 in male hearts with specific LMNA mutations.
Nuclear translocation of FHL2 and SRF in NRCs
The role of AR in nuclear accumulation of FHL2 and SRF was investigated in NRCs transfected with GFP-tagged AR in the presence or absence of testosterone or an AR antagonist, flutamide. GFP-AR and SRF were observed in both cytoplasm and nucleus ( Figure 2D ), while FHL2 was found specifically in the cytoplasm in the most ( 90%) of transfected NRCs ( Figure 2E ). Upon treatment with testosterone, both GFP-AR and SRF translocated to nuclei, whereas FHL2 displayed partial nuclear localization in 80% of the transfected NRCs. On the other hand, the testosterone-induced nuclear accumulation of AR, SRF, and FHL2 was suppressed by flutamide. In addition, silencing of FHL2 by siRNA in NRCs expressing GFP-AR revealed that the preferential nuclear localization of SRF in testosterone-treated cells was mediated by FHL2 (Figure 3 ).
Survival prognosis of Lmna H222P/H222P mice with removal of gonadal organs
The role of sex hormones in the mortality and severity of LMNA-linked DCM was investigated in vivo, where male and female WT (Lmna +/+ ) and Lmna H222P/H222P mice were castrated and ovariectomized, respectively (see Supplementary material online, Figure S7 ). We found that the castration significantly improved survival prognosis of male Lmna H222P/H222P mice, as evidenced by the prolonged 50% survival time (8.09 + 0.27 vs. 10.25 + 0.38 months, P , 0.001) and reduced overall mortality (P , 0.001, log-rank test) ( Figure 4A ). Improvement in mortality observed with ovariectomized Lmna H222P/H222P female mice was not statistically significant (P ¼ 0.10), but the 50% survival time was significantly prolonged by the ovariectomy (10.10 + 0.28 vs. 11.07 + 0.32 months, P , 0.05) ( Figure 4A ). These data demonstrated the beneficial effect of removing gonadal organs on the survival prognosis of Lmna H222P/H222P mice especially in male mice and to only a little extent in female mice.
3.6 Evaluation of cardiac function in Lmna H222P/H222P mice with removal of gonadal organs Cardiac function was evaluated by using transthoracic echocardiography for sham-operated and operated mice at 3-4, 6-7, and 9-10 months of age (see Supplementary material online, Figure S7 ). The sham-operated Lmna H222P/H222P mice, in both male and female, showed progressive LV dilation and contractile dysfunction, as indicated by the decreased LV fractional shortening (LVFS) and LV ejection fraction (LVEF). The castration preserved LVFS and LVEF in males, whereas the ovariectomy showed no significant impact in females ( Table 1 , see Supplementary material online, Figure S8 ). When we measured blood pressure of sham-operated and castrated Lmna H222P/H222P male mice at 4 months of age by the indirect tail-cuff method, the systolic blood pressure was not significantly changed by the castration; sham-operated 121.0 + 3.7 vs. castrated 126.2 + 4.0 mmHg (n ¼ 6 in each group). These data demonstrated that the castration improved LV contractile dysfunction without affecting systolic blood pressure in the Lmna H222P/H222P mice. As for data of ECG, QRS complex duration and PR interval were prolonged, albeit not significant, in the Lmna H222P/H222P mice, in both male and female, as reported previously, 10 but there were no changes by the castration or ovariectomy (see Supplementary material online, Table S3 ).
To directly demonstrate the role of androgen in disease progression, we treated mice with testosterone or flutamide. By the testosterone treatment, cardiac dysfunction was accelerated in the castrated male Lmna H222P/H222P mice. In contrast, progression of cardiac dysfunction was slowed in the flutamide-treated male Lmna H222P/H222P mice ( IVSd, interventricular septal wall thickness in diastole; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PWd, posterior wall thickness in diastole. *P , 0.05, **P , 0.01, and ***P , 0.001, vs. age-, sex-, and genotype-matched Sham-operated mice.
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3.8 Altered expression of genes and proteins related with cardiac remodelling in hearts from Lmna H222P/H222P mice Abnormal regulation of gene or protein expression involved in the sarcomere organization, cardiac hormones, proto-oncogene, and extracellular matrix remodelling is associated with DCM and CHF, 22 and SRF is required for the induction of cardiac remodelling-associated genes including Nppa, Nppb, Myh7, and Fos. 20 We investigated the gene expression profiles in the hearts from Lmna H222P/H222P mice. It was observed that the expression of Nppa, Nppb, and Myh7 at the mRNA level was increased in the hearts from sham-operated male Lmna H222P/H222P mice, and that the up-regulation was suppressed in the hearts from castrated or flutamide-treated male Lmna H222P/H222P mice ( Figure 5 ).
In addition, significant increase in expression of proto-oncogene Fos and extracellular matrix remodelling-related genes, such as Tgfb1, Tgfb2, and Col1a2, was found in the hearts from the sham-operated male Lmna H222P/H222P mice, which were suppressed by the castration or flutamide treatment ( Figure 5) . Expression of Nppa, Nppb, Myh7, and Col1a2 was significantly increased in the hearts from testosteronetreated female Lmna H222P/H222P mice ( Figure 5 ). Moreover, altered expression of atrial natriuretic peptide and b-myosin heavy chain encoded by Nppa and Myh7, respectively, was confirmed at the protein levels (see Supplementary material online, Figure S9 ).
3.9 Accumulation of androgen-related proteins in nuclei of cardiomyocytes from Lmna H222P/H222P mice Next, we investigated the expression of AR in the hearts from Lmna +/+ and Lmna H222P/H222P mice ( Table 2 ). Western blot analyses
showed an increased expression of AR in both total protein and nuclear extracts from the Lmna H222P/H222P hearts, irrespective of gender ( Figure 6A and B). The nuclear accumulation of AR was accompanied by the AR co-factors, SRF and FHL2, in the male Lmna H222P/ H222P hearts, but not in the female Lmna H222P/H222P hearts ( Figure 6C and D) . The increased nuclear accumulation of SRF and FHL2 was suppressed in the castrated male Lmna H222P/H222P mice, whereas no difference was observed in the expression of AR between sham-operated and castrated male Lmna H222P/H222P mice ( Figure 6C ). On the other hand, no nuclear accumulation of AR, SRF, or FHL2 was observed in the soleus muscle from the Lmna H222P/H222P mice (see Supplementary material online, Figure S10 ). These observations suggested that the nuclear accumulation of androgen-related proteins was specific to the heart muscle, not the skeletal muscles, in Lmna H222P/H222P mice, which was consistent with the findings that the gender difference was observed only for cardiac function and not for skeletal muscle symptoms in the Lmna H222P/H222P mice. 10 
Discussion
Sex hormones mediate their function by activation of specific receptors. Upon activation, sex hormone receptors translocate into nuclei, where they bind hormone response elements in the regulatory region of target genes, and, together with co-activators and other transcription factors, initiate transcription. In this context, androgens including testosterone mediate their action via AR, and androgen-activated AR exerts its biological effect via complex formation with co-regulators. 23 In this study, we demonstrated the increased expression and nuclear accumulation of AR in the hearts from the DCM patients carrying the p.R225X mutation and the Lmna H222P/H222P mice. Quite interestingly, we found concomitantly nuclear accumulation of SRF and FHL2 in cardiomyocytes from the human DCM patients and mice. It was reported that SRF and FHL2 formed a complex with AR to act as co-activators of AR-dependent transcription. 24, 25 SRF is required for the induction of cardiac remodelling-related genes including Nppa, Nppb, Myh7, and Fos, 20 of which expression was increased in the Lmna H222P/H222P
hearts. In addition, FHL2 is preferentially expressed in the cardiac muscle and only a little in the skeletal muscles. 26 These observations suggested that the cardiomyocyte-specific nuclear accumulation of AR-FHL2-SRF complex induced by testosterone was involved in the disease progression of DCM caused by specific LMNA mutations. It is noteworthy that overexpression of AR accelerated nuclear accumulation of FHL2 and SRF in NRCs in the presence of testosterone, and silencing of FHL2 suppressed the translocation of SRF into the nuclei. It is therefore implied that a blockade of SRF-AR -FHL2 complex formation might be a therapeutic strategy for adverse effect of testosterone in DCM caused by LMNA mutation. It may be advocating that a high dose testosterone treatment might not be beneficial for CHF, especially for individuals whose AR expression would be increased in the heart, because nuclear accumulation of AR in the cardiac muscles is associated with higher mortality and severity of cardiac dysfunction. Significant gender differences in morbidity and mortality of human CHF including DCM has been recognized. 6, 27, 28 Hormone-replacement therapy appeared to improve survival in post-menopausal women with systolic dysfunction. 29 In addition, it has been demonstrated that males displayed more prominent abnormalities in cardiac function than females, and female-related phenotypes could be mimicked by administration of estradiol in males and ovariectomized females in mice. 8 These observations suggested the role of oestrogen as a cardiac protector. On the other hand, potential influence of androgens on the cardiac hypertrophy and fibrosis in mice was described in some reports, 12, 30 and a low dose testosterone supplementation improves cardiac functional capacity in CHF patients. 31 However, the adverse or beneficial role of androgens in cardiovascular risk is not fully understood. In this study, we revealed a deleterious role of testosterone in the progression of DCM in a mouse model caused by the LMNA mutations. Castration significantly improved cardiac function and survival prognosis of the male Lmna H222P/H222P mice. Interestingly, ovariectomy also improved survival prognosis, albeit to less extent, of the female Lmna H222P/H222P mice. Because a small amount of testosterone is produced in the ovary, it was speculated that a slight improvement of survival prognosis in the ovariectomized female Lmna H222P/H222P mice was due to the elimination of ovarian testosterone. We also demonstrated that the testosterone significantly worsened the cardiac function in the castrated male Lmna H222P/H222P mice and female Lmna H222P/H222P mice, indicating the impact of testosterone on disease progression. Because the increased expression of AR was observed in the hearts from both male and female Lmna H222P/H222P mice, it was suggested that the presence of both testosterone and AR played pivotal roles in the cardiac phenotype of Lmna H222P/H222P mice.
The up-regulation of extracellular matrix remodelling-related genes in the male Lmna Androgen receptor in gender difference of LMNA-linked DCM fibrosis in the female Lmna H222P/H222P mice. It was previously reported that either castration or treatment with flutamide attenuated the cardiac fibrosis in GC-A KO mice. 12 However, nuclear accumulation of AR was not observed in the hearts from the GC-A KO mice in this study. These observations suggested that testosterone played a role in the cardiac remodelling including interstitial fibrosis, but molecular mechanisms underlying the gender difference in the cardiac dysfunction due to the LMNA mutations would be different from that caused by the knock-out of the GC-A gene.
There are some limitations in this study. First, it is not resolved how the specific LMNA mutations lead to the cardiomyocyte-specific nuclear accumulation of AR. Second, we have not evaluated the angiogenesis in the hearts, which is a hallmark of cardiac remodelling. These issues should be further investigated to elucidate the molecular mechanisms for the gender difference.
In conclusion, we revealed that the nuclear accumulation of AR -FHL2-SRF complex was associated with specific LMNA mutations showing the gender difference in disease progression of DCM. We also demonstrated a deleterious effect of testosterone on the DCM phenotypes and survival prognosis in the Lmna H222P/H222P mice. Our findings implicated that a blockade of AR signalling might be beneficial for preserving cardiac function in the DCM patients, when nuclear accumulation of AR could be found in their hearts. Nuclear AR accumulation could be a biomarker for prediction of harmful side effects in testosterone supplement therapy for CHF. 31 
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